Compare ECO & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECO | AMLX |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | Greece | United States |
| Employees | N/A | 136 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2023 | 2021 |
| Metric | ECO | AMLX |
|---|---|---|
| Price | $54.59 | $17.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $42.00 | $21.56 |
| AVG Volume (30 Days) | 467.3K | ★ 1.7M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.12% | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | $16.07 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.60 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $22.38 | $7.48 |
| 52 Week High | $58.45 | $19.15 |
| Indicator | ECO | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 61.15 |
| Support Level | $48.27 | $12.17 |
| Resistance Level | $57.47 | $18.88 |
| Average True Range (ATR) | 2.28 | 1.04 |
| MACD | 0.29 | 0.05 |
| Stochastic Oscillator | 74.55 | 62.35 |
Okeanis Eco Tankers Corp is an international owner and operator of a fleet of tanker vessels used for the transportation of crude oil. Its fleet consists of modern Suezmax and VLCC tankers that are designed in accordance with eco-efficiency standards, including features such as reduced fuel consumption, exhaust gas cleaning systems, and ballast water treatment systems. All of the company's revenue is derived from a single segment, the crude oil tanker segment. Geographically, the maximum revenue is generated from Europe, and the rest from Asia, North America, and South America.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.